Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Australian Prescriber, 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L. +2 more
openaire +6 more sources
Клинический разбор в общей медицине, 2021 The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova +3 more
doaj +2 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents [PDF]
Drugs in Context, 2014 Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj +2 more sources
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review [PDF]
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +3 more sources
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study [PDF]
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +2 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors [PDF]
, 2020 peer ...
Mifsud, Simon +3 more
core +4 more sources
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
Frontiers in Cardiovascular Medicine, 2022 A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Annamaria Mascolo +17 more
doaj +3 more sources
Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure [PDF]
Российский кардиологический журнал, 2021 The article analyzes the new results of randomized clinical trials on the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases, heart failure with and without type 2 diabetes.
E. V. Kovalenko +3 more
doaj +2 more sources
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Cardio-OncologyBackground Immune checkpoint inhibitors (ICIs) have revolutionized the prognosis of cancer. Diabetes mellitus (DM) has been shown to have a negative effect on patients treated with ICIs.
Moran Gvili Perelman +12 more
doaj +3 more sources
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus [PDF]
, 2022 Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failure and
M Evans (7332128) +4 more
core +6 more sources